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In this issue of Blood, the articles by Shaham et al 1 and Wang et al 2 are the first to identify microRNA 486 (miR-486) as a requisite oncomiR and credible therapeutic target in myeloid leukemia of Down syndrome (ML-DS) and chronic myeloid leukemia (CML) by showing that these 2 leukemias co-opt miR-486 functions in normal erythroid progenitor progrowth and survival activity.
T he figure summarizes these 2 independent reports, which delineate the mechanisms leading to the aberrant overexpression of miR-486 in ML-DS and CML (panel A). Their highlights are described in greater detail below. In sum, the articles clearly demonstrate that miR-486 directs erythroid differentiation of normal hematopoietic cells involving activation of the AKT pathway (panel B), which is mirrored by a similar erythroid phenotype signaled through miR-486/AKT in leukemia cells that also acts to promote cell survival (panel C). The extensive and congruent results using human and mouse in vivo and in vitro models combined with primary human leukemia and normal hematopoietic cells underscore the importance of miR-486 as a conserved mediator of erythropoiesis and leukemogenesis. Moreover, these studies provide the initial proof of principle for miR-486 as a therapeutic target in CML and ML-DS, laying the groundwork for follow-up in vivo preclinical testing.
Infants and children with Down syndrome (DS) have significantly increased risk of developing transient myeloproliferative disorder (TMD), which sometimes transforms to myeloid leukemia (ML-DS), the most common subtype being acute megakaryoblastic leukemia (AMKL). 3 Acquired somatic mutations in the megakaryocyte/erythroidlineage specifying transcription factor GATA1 generate a short isoform (GATA1s) that cooperates with trisomy 21 early on in the evolution of TMD and ML-DS. 4 Bone marrow reticulocytes: a Plasmodium vivax affair? In this issue of Blood, Malleret and colleagues show the importance of the bone marrow in Plasmodium vivax biology by proving the preferential infection of young reticulocytes (generally restricted to the bone marrow), which then experience accelerated maturation postinvasion. 1 P lasmodium vivax mainly invades reticulocytes, a heterogeneous population of red blood cell precursors characterized by a reticular network of residual RNA, whose maturation is indicated by the decreasing expression of the transferrin receptor CD71. This host cell specificity shapes P vivax pathobiology, and the strict requirement for reticulocytes has hampered the establishment of an in vitro culture system for this parasite. By sorting different developmental stages of cord blood reticulocytes for use in an ex vivo invasion assay, Malleret and colleagues show that P vivax merozoites prefer the youngest of the young erythrocytes. The immature CD71 1 reticulocytes, generally restricted to bone marrow, were more efficiently invaded than older CD71 2 reticulocytes principally
